Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
Active, not recruiting · NCT05285891 · Registry updated 2026-09-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis | CNS demyelinating autoimmune disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 4 | 2026-09-01 | NCT05285891 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
13 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York | United States | 1 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| MedStar Georgetown University Hospital | Washington D.C. | United States | 204 |
| Northwestern University | Chicago | United States | 727 |
| Oklahoma Medical Research Foundation | Oklahoma City | United States | 12 |
| RWJ Barnabas Health | Livingston | United States | 1 |
| The University of Texas Health Science Center at Houston, McGovern Medical School | Houston | United States | 3 |
| University of Massachusetts Memorial Medical Center | Worcester | United States | 14 |
| University of Pennsylvania, Perelman School of Medicine | Philadelphia | United States | 7 |
| University of Rochester Medical Center | Rochester | United States | 2 |
| University of Texas Southwestern Medical Center | Dallas | United States | 249 |
| Virginia Commonwealth University School of Medicine | Richmond | United States | 6 |
| Yale School of Medicine | New Haven | United States | 31 |